RT Journal Article
SR Electronic
T1 Risk of Severe Outcomes From COVID-19 in Comorbid Populations in the Omicron Era: A Meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.02.24317727
DO 10.1101/2024.12.02.24317727
A1 Chapman, Akvile
A1 Barouch, Dan H.
A1 Lip, Gregory Y. H.
A1 Pliakas, Triantafyllos
A1 Polverino, Eva
A1 Sourij, Harald
A1 Abduljawad, Sultan
YR 2024
UL http://medrxiv.org/content/early/2024/12/03/2024.12.02.24317727.abstract
AB Importance This is the first meta-analysis to investigate risk of death and hospitalization in individuals with comorbidities, specifically during the Omicron era.Objective To assess the risk of mortality and hospitalization from COVID-19 in individuals with comorbidities in comparison with individuals without comorbidities during the Omicron era.Data Sources A systematic search of Embase, MEDLINE, PubMed, Europe PMC, Latin American and Caribbean Health Sciences Literature, Cochrane COVID-19 Study Register, and WHO COVID-19 Database was performed to identify studies published between 1 January 2022 and 13 March 2024.Study Selection Inclusion criteria were observational studies including people (all ages) with at least 1 of the following comorbidities: cardiovascular/ cerebrovascular disease, chronic lung conditions, diabetes, and obesity. In total, 72 studies were included in the review, of which 68 were meta-analyzed.Data Extraction and Synthesis Data were extracted by one reviewer and verified by a second. Studies were synthesized quantitively (meta-analysis) using random-effect models. PRISMA guidelines were followed.Main Outcomes and Measures Evaluated outcomes were the risks of death, hospitalization, intensive care unit (ICU) admission, and any combination of these outcomes. Odds ratios, hazard ratios, and rate ratios were extracted; pooled relative risk (RR) and 95% confidence intervals (CI) were calculated.Results Minimum numbers of participants per comorbidity across included studies ranged from 328 870 for thrombosis to 13 720 480 for hypertension. Risks of death, hospitalization, and the combined outcome were increased in individuals with cerebrovascular disease, COPD, diabetes, respiratory diseases, heart disease, and heart failure versus those without (pooled RRs ranged from 1.27 [heart disease, hospitalization; 95% CI, 1.17-1.38, P < .001] to 1.78 [heart failure, death: 95% CI, 1.46-2.16, P < .001]). Individuals with diabetes and obesity had increased risk of ICU admission (RR: 1.20; 95% CI: 1.04-1.38, P = .0141 and RR: 1.32; 95% CI: 1.11-1.57, P = .00158, respectively).Conclusions During the Omicron era, risk of death and hospitalization from COVID-19 is increased amongst individuals with comorbidities including cerebrovascular/cardiovascular conditions, chronic lung diseases, and diabetes, with the highest risk in those with heart failure. Individuals with diabetes and obesity are at increased risk of ICU admission.Question What are the risks of severe outcomes from COVID-19 in individuals with comorbidities during the Omicron era?Findings This systematic review and meta-analysis found increased risk of mortality and hospitalization among individuals with a range of comorbidities, including cerebrovascular/cardiovascular conditions, chronic lung diseases, and diabetes, with the highest risk in those with heart failure, versus those without. Risk of ICU admission was higher in individuals with obesity and diabetes.Meaning This study identified comorbid populations most at risk of severe outcomes from COVID-19. Targeting these populations with public health measures, such as vaccination, may be beneficial.Competing Interest StatementSA is an employee of BioNtech UK Ltd. DB has no conflicts of interest. AC is an employee of Maverex Ltd., which received consulting fees from BioNTech SE. GL is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Anthos. No fees were received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator. TP receives consulting fees from BioNTech SE, GlaxoSmithKline, UNAIDS, and USAID. EP receives speaker and consultancy fees from Pfizer and Moderna. HS receives consulting fees and speaker's honoraria from Amgen, Amarin, Bayer, Boehringer Ingelheim, Cancom, Daiichi Sankyo, Eli Lilly, NovoNordisk.Funding StatementThis study was funded by BioNTech SE, Mainz, Germany.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Source data can be found in the followed published references: Agrawal U, Bedston S, McCowan C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022;400(10360):1305-1320. AlBahrani S, AlBarrak A, Al-Musawi T, et al. COVID-19 vaccine had a significant positive impact on patients with SARS-COV-2 during the third (Omicron) wave in Saudi Arabia. J Infect Public Health. 2022;15(11):1169-1174. Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis. 2023;23(8):914-921. Bao S, Lu G, Kang Y, et al. A diagnostic model for serious COVID-19 infection among older adults in Shanghai during the Omicron wave. Front Med (Lausanne). 2022;9:1018516. Bedston S, Almaghrabi F, Patterson L, et al. Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales. Lancet Reg Health Eur. 2024;37:100816. Benites-Godinez V, Mendoza-Cano O, Trujillo X, et al. Survival analysis and contributing factors among PCR-confirmed adult inpatients during the endemic phase of COVID-19. Diseases. 2023;11(3):119. Beraud G, Bouetard L, Civljak R, et al. Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1). Clin Microbiol Infect. 2023;29(5):642-650. Briciu V, Topan A, Calin M, et al. Comparison of COVID-19 severity in vaccinated and unvaccinated patients during the Delta and Omicron wave of the pandemic in a Romanian tertiary infectious diseases hospital. Healthcare. 2023;11(3):373. Brosh-Nissimov T, Hussein K, Wiener-Well Y, et al. Hospitalized patients with severe coronavirus disease 2019 during the Omicron wave in Israel: benefits of a fourth vaccine dose. Clin Infect Dis. 2022;76(3):e234-e239. Bulgaresi M, Rivasi G, Tarantini F, et al. Impact of SARS-CoV2 infection on mortality and hospitalization in nursing home residents during the "Omicron era". Aging Clin Exp Res. 2023;35(6):1393-1399. Chan M, Owens L, Gray ML, et al. Asthma and susceptibility to COVID-19 in Australian children during Alpha, Delta and Omicron waves of the COVID-19 pandemic. J Asthma Allergy. 2023;16(null):1139-1155. Chan M, Owens L, Gray ML, et al. Asthma and susceptibility to COVID-19 in Australian children during Alpha, Delta and Omicron waves of the COVID-19 pandemic. J Asthma Allergy. 2023;16(null):1139-1155. Choi S-H, Choi JH, Lee JK, et al. Clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea. J Korean Med Sci. 2023;38(9):e65. de Prost N, Audureau E, Heming N, et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. Nat Commun. 2022;13(1):6025. Drummond PD, de Salles DB, de Souza NSH, et al. Profile and outcomes of hospitalized COVID-19 patients during the prevalence of the Omicron variant according to the Brazilian regions: a retrospective cohort study from 2022. Vaccines. 2023;11(10):1568. Elamin MY, Maslamani YA, Alsheikh FA, et al. Impact of vaccination on morbidity and mortality in adults hospitalized with COVID-19 during the omicron wave in the Jazan Region, Saudi Arabia. Saudi Med J. 2024;45(2):179-187. Ellis RJ, Moffatt CR, Aaron LT, et al. Factors associated with hospitalisations and deaths of residential aged care residents with COVID-19 during the Omicron (BA.1) wave in Queensland. Med J Aust. 2023;218(4):174-179. Favia G, Barile G, Tempesta A, et al. Relationship between oral lesions and severe SARS-CoV-2 infection in intensive care unit patients. Oral Dis. 2024;30(3):1296-1303. Finkas LK, Ramesh N, Block LS, et al. Asthma and COVID-19 outcomes: a prospective study in a large health care delivery system. J Asthma Allergy. 2023;16:1041-1051. Flacco ME, Acuti Martellucci C, Soldato G, et al. Predictors of SARS-CoV-2 infection and severe and lethal COVID-19 after three years of follow-up: a population-wide study. Viruses. 2023;15(9):1794. Flisiak R, Zarębska-Michaluk D, Dobrowolska K, et al. Change in the clinical picture of hospitalized patients with COVID-19 between the early and late period of dominance of the Omicron SARS-CoV-2 variant. J Clin Med. 2023;12(17):5572. Gazit S, Saciuk Y, Perez G, et al. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. BMJ. 2022;377:e071113. Geng Y, Nie Q, Liu F, et al. Understanding clinical characteristics influencing adverse outcomes of Omicron infection: a retrospective study with propensity score matching from a Fangcang hospital. Front Cell Infect Microbiol. 2023;13:1115089. Grannec F, Meddeb L, Tissot-Dupont H, Gentile S, Brouqui P. Pre-hospital management of patients with COVID-19 and the impact on hospitalization. Medicina. 2023;59(8):1440. Griggs EP, Mitchell PK, Lazariu V, et al. Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. Clin Infect Dis. 2024;78(2):338-348. Guo Y, Guo Y, Ying H, et al. In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study. BMC Infect Dis. 2023;23(1):698. Helmy MA, Milad LM, Hasanin AM, et al. Parasternal intercostal thickening at hospital admission: a promising indicator for mechanical ventilation risk in subjects with severe COVID-19. J Clin Monit Comput. 2023;37(5):1287-1293. Hippisley-Cox J, Khunti K, Sheikh A, Nguyen-Van-Tam JS, Coupland CAC. Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study. BMJ. 2023;381:e072976. Jamaati H, Karimi S, Ghorbani F, et al. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID-19 in the Omicron variant era: a national cohort study in Iran. J Med Virol. 2023;95(3):e28607. Karageorgou V, Papaioannou AI, Kallieri M, et al. Patients hospitalized for COVID-19 in the periods of Delta and Omicron variant dominance in Greece: determinants of severity and mortality. J Clin Med. 2023;12(18):5904. Kim SH, Kim T, Choi H, Shin TR, Sim YS. Clinical outcome and prognosis of a nosocomial outbreak of COVID-19. J Clin Med. 2023;12(6):2279. Klein EY, Fall A, Norton JM, et al. Severity outcomes associated with SARS-CoV-2 XBB variants, an observational analysis. J Clin Virol. 2023;165:105500. Lee CM, Kim M, Park SW, et al. Clinical outcomes and immunological features of COVID-19 patients receiving B-cell depletion therapy during the Omicron era. Infect Dis (Lond). 2024;56(2):116-127. Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med. 2022;28(9):1933-1943. Li H, Jia X, Wang Y, et al. Differences in the severity and mortality risk factors for patients hospitalized for COVID-19 pneumonia between the early wave and the very late stage of the pandemic. Front Med (Lausanne). 2023;10:1238713. Li D-J, Zhou C-C, Huang F, Shen F-M, Li Y-C. Clinical features of omicron SARS-CoV-2 variants infection associated with co-infection and ICU-acquired infection in ICU patients. Front Public Health. 2024;11:1320340. Liu Y, Chen D, Li J, et al. Metabolic syndrome is associated with poor Omicron infection prognosis while inactivated vaccine improves the outcome of Coronavirus Disease 2019 among Chinese inhabitants: a retrospective observational study from a Chinese municipality. Vaccines. 2023;11(10):1554. Liu Y, Qi Z, Bai M, et al. Combination of chest computed tomography value and clinical laboratory data for the prognostic risk evaluation of patients with COVID-19. Int J Gen Med. 2023;16:3829-3842. Lu G, Zhang Y, Zhang H, et al. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave. Emerg Microbes Infect. 2022;11(1):2045-2054. Manchanda V, Mitra S, Rafique I, et al. Is Omicron really mild? - Comparative analysis of comorbidities and disease outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants. Indian J Med Microbiol. 2023;45:100391. Mayer C, Woo MS, Brehm TT, et al. History of cerebrovascular disease but not dementia increases the risk for secondary vascular events during SARS-CoV-2 infection with presumed Omicron variant: a retrospective observational study. Eur J Neurol. 2023;30(8):2297-2304. McNeil T, Zhang F, Moffatt S, Emeto TI, Tucker E. Nosocomial COVID-19 infection in the era of vaccination and antiviral therapy. Intern Med J. 2024;54(3):374-381. Mendoza-Cano O, Trujillo X, Rios-Silva M, et al. Association between vaccination status for COVID-19 and the risk of severe symptoms during the endemic phase of the disease. Vaccines. 2023;11(10):1512. Mizrahi Reuveni M, Kertes J, Shapiro Ben David S, et al. Risk stratification model for severe COVID-19 disease: a retrospective cohort study. Biomedicines. 2023;11(3):767. Morris CP, Eldesouki RE, Sachithanandham J, et al. Omicron subvariants: clinical, laboratory, and cell culture characterization. Clin Infect Dis. 2023;76(7):1276-1284. Mosallami Aghili SM, Khoshfetrat M, Asgari A, et al. Association of echocardiographic findings with in-hospital mortality of COVID-19 patients and their changes in one-month follow-up; a cohort study. Arch Acad Emerg Med. 2022;10(1):e85. Mumtaz A, Rehman E, Rahaman MA, Rehman S. Inflammatory biomarkers and cardiac injury in COVID-19 patients. Front Public Health. 2022;10:1024535. Nab L, Parker EPK, Andrews CD, et al. Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health. 2023;8(5):e364-e377. O'Leary AL, Wattengel BA, Carter MT, Drye AF, Mergenhagen KA. Risk factors associated with mortality in hospitalized patients with laboratory confirmed SARS-CoV-2 infection during the period of omicron (B.1.1.529) variant predominance. Am J Infect Control. 2023;51(6):603-606. Parajuli P, Sabo R, Alsaadawi R, et al. Fibrosis-4 (FIB-4) index as a predictor for mechanical ventilation and 30-day mortality across COVID-19 variants. J Clin Transl Sci. 2023;7(1):e213. Parra-Bracamonte GM, Lopez-Villalobos N, Velazquez MA, et al. Comparative analysis of risk factors for COVID-19 mortality before, during and after the vaccination programme in Mexico. Public Health. 2023;215:94-99. Patton MJ, Orihuela CJ, Harrod KS, et al. COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. Crit Care. 2023;27(1):34. Radhakrishnan N, Liu M, Idowu B, et al. Comparison of the clinical characteristics of SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) infected patients from a single hospitalist service. BMC Infect Dis. 2023;23(1):747. Russell SL, Klaver BRA, Harrigan SP, et al. Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population-based cohort study in British Columbia, Canada. J Med Virol. 2023;95(1):e28423. Sardinha DM, Ferreira ALdS, Guimaraes RJdPSe, Lima KVB, Lima LNGC. Clinical characteristics and outcomes among vaccinated and unvaccinated patients with cardiovascular disease who were hospitalized for COVID-19 in Brazil: retrospective cohort. Vaccines (Basel). 2023;11(4):861. Shakor ASaA, Samsudin EZ, Chen XW, Ghazali MH. Factors associated with COVID-19 brought-in deaths: a data-linkage comparative cross-sectional study. J Infect Public Health. 2023;16(12):2068-2078. Shi HJ, Yang J, Eom JS, et al. Clinical characteristics and risk factors for mortality in critical COVID-19 patients aged 50 years or younger during Omicron wave in Korea: comparison with patients older than 50 years of age. J Korean Med Sci. 2023;38(28):e217. Simmons AE, Amoako A, Grima AA, et al. Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: a retrospective cohort study. PLoS One. 2023;18(3):e0283715. Skarbinski J, Wood MS, Chervo TC, et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: a retrospective cohort study. Lancet Reg Health Am. 2022;12:100297. Sonaglioni A, Lombardo M, Albini A, et al. Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period. Front Immunol. 2022;13:958418. Stepanova M, Lam B, Younossi E, et al. The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19. BMC Infect Dis. 2022;22(1):702. Tsujimoto Y, Kobayashi M, Oku T, et al. Outcomes in novel hospital-at-home model for patients with COVID-19: a multicentre retrospective cohort study. Fam Pract. 2023;40(5-6):662-670. Vo AD, La J, Wu JT, et al. Factors associated with severe COVID-19 among vaccinated adults treated in US veterans affairs hospitals. JAMA Netw Open. 2022;5(10):e2240037. Wang X, Zein J, Ji X, Lin DY. Impact of vaccination, prior infection, and therapy on Omicron infection and mortality. J Infect Dis. 2023;227(8):970-976. Ward IL, Robertson C, Agrawal U, et al. Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England. Nat Commun. 2024;15(1):398. Xin S, Chen W, Yu Q, Gao L, Lu G. Effect of the number of coronavirus disease 2019 (COVID-19) vaccination shots on the occurrence of pneumonia, severe pneumonia, and death in SARS-CoV-2-infected patients. Front Public Health. 2024;11:1330106. Yang H, Wang Z, Zhang Y, et al. Clinical characteristics and factors for serious outcomes among outpatients infected with the Omicron subvariant BF.7. J Med Virol. 2023;95(8):e28977. Ying-Hao P, Yuan-Yuan G, Hai-Dong Z, et al. Clinical characteristics and analysis of risk factors for disease progression of patients with SARS-CoV-2 Omicron variant infection: a retrospective study of 25207 cases in a Fangcang hospital. Front Cell Infect Microbiol. 2022;12:1009894. Zhang Y, Han J, Sun F, et al. A practical scoring model to predict the occurrence of critical illness in hospitalized patients with SARS-CoV-2 omicron infection. Front Microbiol. 2022;13:1031231. Zhao Q, Zheng B, Han B, et al. Is azvudine comparable to nirmatrelvir-ritonavir in real-world efficacy and safety for hospitalized patients with COVID-19? a retrospective cohort study. Infect Dis Ther. 2023;12(8):2087-2102. Zhu Z, Cai J, Tang Q, et al. Circulating eosinophils associated with responsiveness to COVID-19 vaccine and the disease severity in patients with SARS-CoV-2 omicron variant infection. BMC Pulm Med. 2023;23(1):177.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.